Crossover Study to Compare the Pharmacokinetics and Bioavailability of a Novel Furosemide Regimen Administered Subcutaneously vs. the Same Dose Administered Intravenously in Subjects With Chronic Heart Failure

NCT02329834 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

23

Enrollment

INDUSTRY

Sponsor class

Conditions

Heart Failure

Interventions

DRUG: Fursemide Injection Solution for subcutaneous administration (80 mg)
DRUG: Furosemide Injection, USP

Sponsor

scPharmaceuticals, Inc.